[go: up one dir, main page]

AR092169A1 - Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla - Google Patents

Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla

Info

Publication number
AR092169A1
AR092169A1 ARP130102935A ARP130102935A AR092169A1 AR 092169 A1 AR092169 A1 AR 092169A1 AR P130102935 A ARP130102935 A AR P130102935A AR P130102935 A ARP130102935 A AR P130102935A AR 092169 A1 AR092169 A1 AR 092169A1
Authority
AR
Argentina
Prior art keywords
oralally
antiparasitary
administrable
pharmaceutical
prepare
Prior art date
Application number
ARP130102935A
Other languages
English (en)
Inventor
Alejandro Fiore Esteban
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50387067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092169(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of AR092169A1 publication Critical patent/AR092169A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una composición farmacéutica sinérgica para el tratamiento de parasitosis humana de Mebendazol (MBDZ) con Nitazoxanida (NTZX), que amplía significativamente el espectro del MBDZ contra protozoos y refuerza la acción antihelmíntica de la NTZX.
ARP130102935A 2012-09-27 2013-08-16 Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla AR092169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/055166 WO2014049397A1 (es) 2012-09-27 2012-09-27 Composición sinérgica de nitazoxanida y mebendazol, procesos para prepararla y el uso de dicha composición para el tratamiento de la parasitosis humana

Publications (1)

Publication Number Publication Date
AR092169A1 true AR092169A1 (es) 2015-03-25

Family

ID=50387067

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102935A AR092169A1 (es) 2012-09-27 2013-08-16 Composicion farmaceutica sinergica adaptada para ser administrable oralmente como antiparasitario y procesos para prepararla

Country Status (10)

Country Link
US (1) US20150250765A1 (es)
EP (1) EP2902024B1 (es)
AR (1) AR092169A1 (es)
BR (1) BR112015006861B1 (es)
CL (1) CL2015000778A1 (es)
CR (1) CR20150190A (es)
MX (1) MX340272B (es)
NI (1) NI201500045A (es)
UY (1) UY34967A (es)
WO (1) WO2014049397A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2610791B1 (es) * 2016-12-22 2018-02-07 Elena TEIJEIRA PRIETO Uso del mebendazol para la eliminación de los gusanos de fuego en acuarios de arrecife
CN111494327B (zh) * 2020-06-23 2023-09-05 瑞阳制药股份有限公司 甲苯咪唑咀嚼片的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657267A (en) 1969-06-20 1972-04-18 Janssen Pharmaceutica Nv Benzimidazole carbamates
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US20050171169A1 (en) * 2004-02-02 2005-08-04 Rossignol Jean F. Combination chemotherapy for helminth infections
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby

Also Published As

Publication number Publication date
US20150250765A1 (en) 2015-09-10
EP2902024B1 (en) 2017-11-29
BR112015006861A2 (pt) 2017-07-04
MX2015003941A (es) 2015-07-21
EP2902024A4 (en) 2016-06-22
CL2015000778A1 (es) 2015-08-21
BR112015006861B1 (pt) 2021-10-13
MX340272B (es) 2016-06-30
CR20150190A (es) 2015-07-09
NI201500045A (es) 2016-02-16
EP2902024A1 (en) 2015-08-05
WO2014049397A1 (es) 2014-04-03
UY34967A (es) 2014-04-30

Similar Documents

Publication Publication Date Title
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002145A1 (es) Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014)
DOP2015000156A (es) Derivados de exendina-4 funcionalizada
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
MX2015003416A (es) Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CO6511249A2 (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
GT201400003A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
MX2017004998A (es) Composicion que contiene un extracto o fraccion de una planta del genero justicia.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
MX386144B (es) Inmunopotenciador.
CR20150377A (es) Composición antfúngicida tópica para el tratamiento de onicomcosis
MX2015007164A (es) Uso de estracto de fenogreco para mejorar la libido femenina.
BR112016012248A2 (pt) método de tratamento de nefropatia
UY35695A (es) Composicion para el tratamiento contra el envejecimiento de la piel

Legal Events

Date Code Title Description
FB Suspension of granting procedure